A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Part of paid clinical trials in Chandler, Arizona.
- Sponsor
- Eccogene
- Study ID
- NCT07288138
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Placebo — DRUGPlacebo will be administered as matching oral capsules.
- ECC4703 — DRUGECC4703 will be administered as oral capsules.
- ECC0509 — DRUGECC0509 will be administered as oral capsules.
- ECC4703 — DRUGECC4703 will be administered as oral capsules.
Study Details
The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.
Key Dates
- Start date
- Dec 15, 2025
- Status verified
- Jun 2026
- Primary completion
- Sep 15, 2027
- Completion
- Sep 29, 2027
Study Design
- Enrollment
- 160 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: Placebo
- Experimental: ECC4703 Low Dose
- Experimental: ECC4703 High Dose
- Experimental: ECC4703 High Dose + ECC0509 High Dose
- Experimental: ECC0509 Low Dose
- Experimental: ECC0509 High Dose
Primary Outcome Measure
Relative Change from Baseline in Liver Fat Content by MRI-PDFF, Comparing ECC4703 Monotherapy Versus Placebo [ Time Frame: Baseline and Week 12 ]
Central Contacts
- Eccogene Clinical Trials86-21-61053022
Locations (58)
Find similar trials in Chandler, AZ
Related Studies
- A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)PHASE1/PHASE2 · Recruiting · Regeneron Pharmaceuticals · Chandler, Arizona
- A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASHPHASE2 · Recruiting · Boston Pharmaceuticals · Chandler, Arizona
- Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled TrialRecruiting · Pichamol Jirapinyo, MD, MPH · Boston, Massachusetts